<p><strong>Patients with neutropenia</strong>: The safety and efficacy of Tedizolid in patients with neutropenia (neutrophil counts &lt;1000 cells/mm3) have not been adequately evaluated. In an animal model of infection, the antibacterial activity of Tedizolid was reduced in the absence of granulocytes. Consider alternative therapies in neutropenic patients.<br />
<br />
<strong>Clostridium difficile-associated diarrhea</strong>: Evaluate if diarrhea occurs.</p>